Element Capital Management’s Matinas BioPharma MTNB Stock Holding History

Element Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,019	Closed	-$231K	–	801
2018 Q3	$231K	Sell	5,019 -2,852	-36%	-$61.3K	﹤0.01%	704
2018 Q2	$171K	Buy	+7,871	New	+$227K	﹤0.01%	753

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Element Capital Management's MTNB Position: Q4 2018 in Review

Element Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2018, closing a stake of 5,019 shares — an estimated $231K sold.

Element Capital Management first reported a position in MTNB in Q2 2018 and held it in 2 quarters. The position peaked at $231K in Q3 2018. 35 funds tracked by Wall St. Rank hold MTNB as of Q4 2018.

Element Capital Management reported no remaining Matinas BioPharma position as of Q4 2018 after selling out during the quarter.
Element Capital Management sold 5,019 Matinas BioPharma shares in Q4 2018, an estimated $231K.
Element Capital Management first reported a position in Matinas BioPharma in Q2 2018 and held it in 2 quarters.
Element Capital Management's Matinas BioPharma position peaked at $231K in Q3 2018.
35 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.